De medewerkers van SHM geven met regelmaat presentaties waarin bevindingen uit onderzoek en publicaties worden gepresenteerd. Een groot gedeelte van de presentaties is Engelstalig. Hieronder vindt u een overzicht van de presentaties in 2004.
We studied demographic changes in the HIV-infected population and the introduction of non-B subtypes in the Netherlands. Patients infected via heterosexual contact and patients originating from HIV-endemic areas form a substantial and increasing part of the HIV-infected population in the Netherlands. Non-B subtypes are hardly found amongst patients originating from the Netherlands. The distribution of subtypes suggests that infections amongst sub-Saharan Africans living in the Netherlands thus far result from import from sub-Saharan Africa and transmission within groups of sub-Saharan Africans.
International Aids Conference Web site
The initial virological and immunological response to HAART is a strong predictor for disease outcome. Using this response we estimated the probability of future death for previously antiretroviral therapy naïve patients. These estimated probabilities were compared with those observed in the general population in the Netherlands. The higher mortality in HIV-infected patients compared to the general population is independent of age and gender. Standardised mortality ratios (SMRs) decrease with older age and higher CD4 counts. SMRs are higher for women than for men as the general population mortality of women is lower than for men of the same age. For successfully HAART treated patients, SMRs are comparable to those in diabetes patients. However, only 16% of the patients accomplish these CD4 counts after 24 weeks.
Reports from several countries show that 10-30% of recent HIV-1 infections carry mutations conferring drug-resistance. Here we report the prevalence of resistant HIV-1 strains among new infections in the Netherlands between 1994 and 2004. Since the introduction of HAART in 1996, transmission of drug-resistant HIV-strains in the Netherlands infections and does not increase over time. This is reflected by the similar prevalence of resistance patients. It is important to keep monitoring baseline resistance as this trend might change.